Illumina Reports 4 Percent Revenue Decline for Q4; Rejects Roche Offer Again | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Illumina reported after the close of the market Tuesday that its fourth-quarter revenues dropped 4 percent year over year, while issuing a separate statement once again rejecting Roche's offer to acquire the company for $44.50 per share, or $5.7 billion.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.